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drives microsatellite instability (MSI). Cells with MSI accumu-
late numerous frameshift mutations. Frameshift mutations
affecting cancer-related genes may promote tumorigenesis and,
therefore, are shared among independently arising MSI tumors.
Consequently, such recurrent frameshift mutations can give
rise to shared immunogenic frameshift peptides (FSPs) that
represent ideal candidates for a vaccine against MSI cancer.
Pathogenic germline variants of mismatch repair genes cause
Lynch syndrome (LS), a hereditary cancer syndrome affecting
approximately 20–25 million individuals worldwide. In-
dividuals with LS are at high risk of developing MSI cancer.
Previously, we demonstrated safety and immunogenicity of an
FSP-based vaccine in a phase I/IIa clinical trial in patients witha history of MSI colorectal cancer. However, the cancer-
preventive effect of FSP vaccination in the scenario of LS has
not yet been demonstrated. METHODS: A genome-wide data-
base of 488,235 mouse coding mononucleotide repeats was
established, from which a set of candidates was selected based
on repeat length, gene expression, and mutation frequency. In
silico prediction, in vivo immunogenicity testing, and epitope
mapping was used to identify candidates for FSP vaccination.
RESULTS: We identified 4 shared FSP neoantigens (Nacad
[FSP-1], Maz [FSP-1], Senp6 [FSP-1], Xirp1 [FSP-1]) that
induced CD4/CD8 T cell responses in naïve C57BL/6 mice.
Using VCMsh2mice, which have a conditional knockout of Msh2
in the intestinal tract and develop intestinal cancer, we showed
vaccination with a combination of only 4 FSPs significantly
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Lynch syndrome tumors are characterized by DNA
mismatch repair deficiency and microsatellite instability,
which gives rise to tumor-specific, mutation-induced,
frameshift peptide neoantigens.
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tumor burden, and prolonged overall survival. Combination of
FSP vaccination with daily naproxen treatment potentiated
immune response, delayed tumor growth, and prolonged sur-
vival even more effectively than FSP vaccination alone. CON-
CLUSIONS: Our preclinical findings support a clinical strategy
of recurrent FSP neoantigen vaccination for LS cancer
immunoprevention.NEW FINDINGS
We demonstrate, in a hereditary cancer model, that tumor
prevention by vaccination with mutation-induced
neoantigens is feasible and effective.
LIMITATIONS
The results are restricted to a mouse model, and clinical
effectiveness of a tumor-preventive neoantigen-based
vaccine needs to be demonstrated in a clinical trial.Keywords: Colorectal Cancer; Frameshift Neoantigens; Lynch
Syndrome; Mouse Model; Preventive Cancer Vaccine.
ismatch repair deficiency (MMRD) is an importantIMPACT
Vaccination against microsatellite instability–induced
frameshift peptide neoantigens prevents tumors in a
mouse model. The vaccine strategy therefore holds
great promise for individuals with Lynch syndrome.
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ATMmechanism driving mutagenesis and genomic
instability in human cancers. MMR-deficient cells accu-
mulate numerous somatic mutations, including insertion/
deletion (indel) mutations, predominantly altering re-
petitive microsatellite (MS) sequences.1,2 Indels in coding
MS promote translational frameshifts, which also
generate truncated frameshift peptide (FSP)-encoding
neoproteins.3 Several studies have identified a large
spectrum of genes affected by such frameshift mutations,
demonstrating that indel mutations affecting key tumor
suppressors, such as the TGFBR2, are enriched in MMRD
cancers.4–6
MMRD cancers can develop sporadically or from he-
reditary predisposition as part of Lynch syndrome (LS). LS
causes up to 2%–5% of all colorectal cancers (CRCs),7 as
well as endometrial, ovarian, uroepithelial, and other can-
cers.8 The estimated population incidence of LS is 1:225–
1:360.9,10 Affected individuals have an estimated 20%–70%
lifetime risk of developing cancer.11,12 LS is caused mainly
by heterozygous germline mutations in one of the MMR
genes MSH2, MLH1, MSH6, or PMS2.13,14 Inactivation of both
alleles of an individual MMR gene is required to cause the
MMRD, typically by somatic “second hit” inactivation of the
functional MMR allele.15,16
MMRD CRCs display distinct clinicohistopathologic fea-
tures that are directly related to the high FSP load. Most
importantly, these include increased infiltration with lym-
phocytes, memory T cells, and improved survival compared
to patients with low tumor-infiltrating lymphocyte CRC.17–19
Accordingly, MMRD tumors are among the most responsive
to immune checkpoint inhibitors that enhance endogenous
anti-tumor adaptive immunity, which is driven predomi-
nantly by FSPs.20
The existence of shared FSP neoantigens in MMRD
cancers creates a mechanism-based framework for novel
tumor immunopreventive approaches.3 Immunologic
studies performed by our group and others have identified
several immunogenic microsatellite instability (MSI)-asso-
ciated FSPs in MMRD CRCs that are recognized by, and
promote proliferation of, cytotoxic T cells.21,22 Importantly,
endogenous adaptive immunity against FSPs is detected in
MMRD cancer patients, and also in tumor-free LS “pre-
vivors,” suggesting a role for immune surveillance in LS
mutation carriers.23Vaccination with recurrent FSPs that are shared by
multiple MMRD tumors of different patients is a promising
approach to boost immune surveillance of MMRD precan-
cerous cell clones, and potentially immune-interception of
subclinical MMRD tumors for effective immunoprevention.3
Recently, we performed a therapeutic phase IIa clinical trial
demonstrating the safety and immunologic efficacy of a
trivalent recurrent FSP-based vaccine in patients with a
history of MMRD MSI CRC.24 However, whether recurrent
FSP vaccination can reduce LS/sporadic MMRD tumor
burden and prolong patient survival, in addition to boosting
anti-tumor immunity, is unknown.
Nonsteroidal anti-inflammatory drugs (NSAIDs), partic-
ularly aspirin (acetylsalicylic acid [ASA]), have been studied
intensively for gastrointestinal cancer prevention. NSAIDs
reduce cyclooxygenase-1 and -2 production of prosta-
glandin E2, which binds to EP1–4 receptors.25 Prostaglandin
E2 drives intestinal tumorigenesis by both promoting pro-
tumorigenic EP2/4-driven intestinal epithelial and stem
cell proliferation and inhibiting immune surveillance and
immune-interception of tumor neoantigens.26,27 ASA
reduces LS CRC incidence and is widely used for LS
gastrointestinal cancer prevention.25,28 However, a recent
large-scale (approximately 20,000 participants) randomized
clinical trial in community-dwelling older (65 years and
older) men and women has raised questions about whether




ATASA might actually increase overall pan-cancer rates and
mortality, at least in older adults.29 Recently, naproxen
(NAP), a propionic acid NSAID derivative, has shown pro-
nounced cancer-preventive activity in LS mouse models and
increased immune surveillance in LS patients.30,31
LS mouse models have provided many important
mechanistic and translational insights. Intestinal epithelial-
specific MMRD mouse models, such as VCMsh2,32 closely
resemble the clinical phenotype seen in LS CRC patients
because they specifically develop intestinal tumors, whereas
constitutional MMRD mice (eg, Msh2null) most frequently
develop T cell lymphomas, which confounds survival anal-
ysis.33 Previously, we described a set of candidate coding
mononucleotide repeat (cMNR) frameshift mutations in a
small number of MSI mouse tumors and detected human/
mouse orthologous conserved cMNR repeats.34 Here, we
used VCMsh2 mice to test the hypothesis that recurrent FSP
vaccination alone or in combination with NSAID treatment
can promote anti-FSP adaptive immunity sufficiently to
reduce intestinal tumor burden and prolong overall
survival.Materials and Methods
Selection of Frameshift Peptides for Vaccination
Computational analysis of mouse genome to
identify coding microsatellites. Search tools and algo-
rithms developed and applied previously for the human cMNR
database (www.seltarbase.de)34–36 were adapted accordingly
to detect all cMNRs in the mouse genome. Perl scripts were
developed to use the ensembl API (www.ensembl.org/info/
docs/api/) and a rigorous redundancy check at the 98% level
was applied. All annotation-based cMNRs with a minimal
repeat length of 4 mononucleotides were retrieved. Using
several filters, repeat tracts within pseudogenes, vector se-
quences, as well as homopolymeric nucleotide stretches at the
most 50 or 30 ends of sequences, were excluded. Candidate se-
quences were stored in a relational database for further anal-
ysis (http://www.bork.embl.de/Docu/yuan/rpt/). Processing
through this analysis pipeline was based on gene sequence data
of the Mus musculus Ensembl release version 77_38.
Mutation and expression analysis of coding
mononucleotide repeats in VCMsh2 formalin-fixed,
paraffin-embedded tumors. For MSI classification of
identified tumors, 4 long noncoding MS markers were used
(mA24, mA27, mT27, and mA33z34,37). Marker MSI was defined
by the occurrence of novel peaks in tumor compared to normal
tissue. Tumor was scored as MSI if at least 1 of 4 markers
showed instability. For polymerase chain reaction–based indel
mutation analysis, a candidate set of 56 cMNRs (Supplementary
Figure 1 and Supplementary Table 1) was selected. These
cMNR candidates were chosen based on repeat length (8 or
more nucleotides), representation of all 4 nucleotides, tran-
script isoform coverage, and robust cMNR amplification.
Predicted Computational NetMHC and SYFPETHI
Immunogenicity of frameshift peptides. To predict the
potential immunogenicity of FSPs resulting from cMNR muta-
tions, peptide sequences were submitted to online available
epitope prediction tools SYFPEITHI (www.syfpeithi.de) and
netMHC4.0 (http://www.cbs.dtu.dk/services/NetMHC/).Searches were performed for major histocompatibility complex
(MHC) class I antigens present in C57BL/6mice (H2-Db and -Kb
alleles). For SYFPEITHI, the calculated score was recorded, for
netMHC4.0, the predicted percentage rank indicating MHC
binding likelihood and the number of predicted strong binders
and weak binders (corresponding to an affinity lower than 50
mM and 500 mM, respectively) were recorded for each peptide.
Evaluation of frameshift peptide immunogenicity
in C57BL/6 mice. FSPs were synthesized by Genaxxon (Ulm,
Germany). Details of peptide solution are described in the
Supplementary Material. For preparation of the vaccine for-
mulations, 50 mg of 3 to 4 FSPs were mixed with 50 mg of
ovalbumin (OVA) 257–264 and OVA 323–339 each and 20 mg
CpG ODN 1826; the mixture was suspended in a final injection
volume of 50 mL in phosphate-buffered saline.
Control vaccine formulations without FSPs was prepared as
described above, adding phosphate-buffered saline in place of
the FSPs. Vaccine mixes were administered 4 times in biweekly
intervals to C57BL/6 mice. All vaccines were administered
subcutaneously into the left or right flank of each mouse. One
week after the last vaccination, cellular immune responses
were measured using interferon (IFN)-gamma enzyme-linked
immunosorbent spot (ELISpot) assay from splenocytes. Hu-
moral FSP-specific immune responses were measured using
peptide enzyme-linked immunosorbent assay. Reactions
significantly above background after subtraction of no-peptide
control spots and SDs of the peptide and the control spot
counts were considered as positive. Assays for determining
cellular and humoral immune responses were performed ac-
cording to previously established protocols described in the
Supplementary Material. Detailed protocols for adjuvant opti-
mization are provided in the Supplementary Material.Immunoprevention in VCMsh2 Mice
Mouse strains and tissue collection. Villin-Cre mice
were bred to Msh2 LoxP/LoxP mice to generate VCMsh2 mice in
the laboratory of Winfried Edelmann previously.32 Mice were
genotyped to confirm the status of Cre transgene and floxed
Msh2, respectively. Mice with the Villin promoter used to drive
expression of Cre recombinase and Msh2 exon 12 flanked by
LoxP sites (VCMsh2) mice on the C57BL/6 genetic background32
were bred and housed in a specific pathogen–free barrier fa-
cility at Weill Cornell Medical College according to Institutional
Animal Care and Use Committee guidelines.
Cancer prevention and vaccination proto-
cols. Control mice were given pelleted plain New Western
Diet 1 (Research Diets). ASA and NAP were purchased from
Spectrum Chemicals Inc in powder form. ASA- or NAP-
impregnated, pelleted New Western Diet 1 (400 ppm ASA or
166 ppm NAP) were given at the age of weaning to mice
assigned to those arms. For FSP vaccination, all peptides (Nacad
[FSP-1], Xirp1 [FSP-1], Maz [FSP-1]), and Senp6 [FSP-1]) were
custom made by Thermo Fisher Scientific at >98% purity and
the adjuvant CpG ODN1826 was purchased from InvivoGen.
Vaccine components were prepared following manufacturer’s
protocol in dimethyl sulfoxide and combined fresh before each
vaccination. The study consists of the following 6 arms: con-
trols, vaccine only, NAP only, ASA only, vaccine þ NAP, and
vaccine þ ASA. Starting at the age of 6–8 weeks, mice enrolled
in FSP vaccine alone and FSP vaccine þ NSAID arms were













ATvaccinated subcutaneously in either left or right hind 4 times
biweekly, followed by 4 times monthly. Per shot, each mouse
received 50 mg of each FSP combined with 20 mg of the
adjuvant.
Each treatment group was populated with 16–20 mice on a
rolling basis for efficacy studies. Mice were monitored over
their lifetime by Research Animal Resources and Compliance
Veterinary Services and the investigator twice a week for the
following signs to determine euthanasia: weight loss, poor coat
quality, hunched posture, and pale limbs (anemia). Following
the Institutional Animal Care and Use Committee guidelines,
mice presenting with these signs were euthanized by CO2
inhalation.
Regulatory compliance. All VCMsh2 mice were housed
in isolation units approved by the Weill Cornell Institutional
Animal Care and Use Committee (protocol number: AC-
AAAN5700). The mice used in trials were allowed to run free
in the cage, were fed the Western diet or NSAID-containing
matched diet (Research Diets), and were provided water ad
libitum. The Animal Care Facilities at German Cancer Research
Center were used for housing C57BL/6 mice for frameshift
peptide selection. The German Cancer Research Center facilities
have been approved by The Federation of European Laboratory
Animal Science Associations and accredited. Adjuvant optimi-
zation studies were performed in the Frederic National labo-
ratory according to Institutional Review Board and Animal Care
and Use Committee regulations.
Immunohistochemistry. Immunohistochemistry stain-
ing was performed on formalin-fixed, paraffin-embedded tis-
sues from intestinal tumors taken from VCMsh2 mice treated
with NAP with or without the tetravalent FSPs vaccine ac-
cording to standard protocols (see Supplementary Methods).
The following primary antibodies were used for CD3: clone SP7
abcam ab16669; for CD4: clone 4SM95 ThermoFisher Scientific
#14-9766-82; for CD8: clone 4SM15 ThermoFisher Scientific
#14-0808-82; for Foxp3: clone FJK-16s ThermoFisher Scienti-
fic #14-5773-82; for PD-1: clone EPR20665 abcam ab214421.
The following biotinylated secondary antibodies were used for
CD3 and PD-1: Vector Laboratories BA-1100; and for CD4, CD8
and Foxp3: Vector Laboratories BA-9401.
Immune cell quantification. The tissue slides were
scanned with a NanoZoomer S210 slide scanner (Hamamatsu,
Japan) with a scanning resolution of 0.23 mm/pixel in the 40
mode. The 3,30-diaminobenzidine tetra hydrochloride
chromogen–positive stained cells were identified with QuPath
(version 0.1.238) using the positive cell detection feature in at
least 1 region of interest with an area of 0.25 mm2 within each
tumor slide. The number of positive cells was counted and
recorded. Tissue sections with insufficient quality or with no
staining signal detectable in the entire section were excluded
from the analysis.
Statistical evaluation. Mann-Whitney tests comparing
the FSP vaccine group with the control group were per-
formed using GraphPad Prism software, version 8.2.1 for
Windows (GraphPad Software, San Diego, CA). GraphPad
was also used to generate dot plots. Mann-Whitney com-
parisons of tumor burden (sum of all intestinal tumor
weights per mouse) and Kaplan-Meier curve overall survival
analyses were also performed using GraphPad Prism. Sta-
tistical analyses of adjuvant comparison results wereconducted with GraphPad Prism 7 software using one-way
analysis of variance nonparametric analysis with the
Kruskal-Wallis multiple comparisons test. P < .05 was
considered significant.Results
Computational Identification of Mouse Genome
Coding Microsatellites
A multistep strategy was employed to develop a mouse
vaccine composed of the most immunogenic FSP candidates
and to test their efficacy in immunocompetent VCMsh2 mice
(Figure 1).
Using a computational approach, we established a
genome-wide database of coding MS in the mouse genome.
This database comprises 488,235 cMNRs consisting of 4 or
more nucleotides in length (Figure 2). Because increased
repeat length correlates with increased cMNR mutation
probability,5,6 we focused our subsequent analyses on
cMNRs with a repeat length of 8 or more nucleotides.Coding Mononucleotide Repeat Frameshift
Mutation Patterns in Intestinal Tumors of
VCMsh2 Mice
For mutational analyses of candidate cMNRs, intestinal
adenomas and carcinomas, as well as normal mucosae, from
the same animals were collected from VCMsh2mice (n ¼ 25;
aged between 7 and 15 months, 1 tumor per animal). Tu-
mors were confirmed as MSI/MMRD when analyzed by a
panel of mononucleotide repeats (mA24, mA27, mT27, and
mA33) previously established as sensitive and specific for
MSI detection in mouse tumors.5 Frameshift mutation ana-
lyses were performed on a selected subset of 56 cMNR
candidates that showed increased repeat length (8 or more
nucleotides), represented all 4 nucleobases, covered
different transcript isoforms, and allowed robust amplifi-
cation from formalin-fixed, paraffin-embedded tissue spec-
imens (Supplementary Figure 1). The majority of these
cMNR candidates (36 of 56 [64.3%]) carried frameshift
mutations in 1 or more tumors, with mutation frequencies
ranging from 6.5% to 75% (Supplementary Figure 1). After
eliminating candidates polymorphic in normal tissue and/or
showing a mutation frequency of <15% in tumors, we
further evaluated 13 remaining cMNR candidate genes and
confirmed their expression in normal and tumor tissues by
reverse transcription polymerase chain reaction.In Silico Prediction of Frameshift Peptide
Immunogenicity
We next searched for potential immunogenic MHC
binding motifs in 26 FSP neopeptides derived from (–1) and
(–2) indel mutations affecting these 13 cMNRs (Table 1).
Using epitope prediction tools netMHC4.0 and SYFPEITHI
1.0, a subset of 10 FSPs turned up as potentially immuno-
genic candidates and were selected for subsequent
Figure 1. Experimental strategy for developing a murine FSP vaccine.
Figure 2. Distribution of cMNRs in the mouse genome. The
occurrence of cMNRs is shown according to repeat type and
length (8 or more nucleotides).




ATimmunologic analyses. Based on our mutation data, these
10 FSPs covered most of the analyzed tumors (15 of 16
[93%])Induction of Frameshift Peptide–Specific Cellular
and Humoral Immune Responses inC57BL/6Mice
The immunogenicity of 10 FSPs with highest in silico
prediction scores was experimentally evaluated in C57BL/6
mice (Figure 3A). To determine induction of antigen-specific
T cell responses, ex vivo IFN-gamma ELISpot assays were
performed. Four of 10 FSP neoantigens, that is, Maz (FSP-1),
Nacad (FSP-1), Xirp1 (FSP-1), and Senp6 (FSP-1), triggered
the induction of T cell responses significantly above back-
ground in vaccinated C57BL/6 mice (Figure 3B). Vaccination
was repeated using a mixture of the 4 positive candidates,
and ELISpot was repeated for each peptide separately to
validate the immunogenicity of FSP neoantigens when
Table 1.Mutation frequency of cMNR and FSP Sequences
Gene





Type Monomorphic Normal Tumor Total FS-specific Db Kb % Rank
Nacad C14 Yes Yes Yes 75 FS(–1) 56.25 VIYAPPPPAEGRWPCWLLRAH*a 15 s0 w0 s0 w0 3
FS(–2) 37.5 DVIYAPPPQQRGGGRAGYSERIDGQRDRETGV GTR
PGHARGGCGR*a
14 s0 w0 s0 w0 6
Xirp1 C9 Yes Yes Yes 37.5 FS(–1) 31.25 GKGPGGPPLSSPKRVMYRLSVGCLRPTL*a 19 s0 w2 s1 w4 0.4
FS(–2) 6.25 GKGPGGPP* — — — —
5730596B20Rik C12 Yes Yes Yes 37.5 FS(–1) 37.5 GTLPPPPPTQH* 6 s0 w0 s0 w0 39
FS(–2) 0.00 LGTLPPPPQPSTEQSGWKHHQ* 7 s0 w0 s0 w0 55
Rif1 A12 Yes Yes Yes 33.3 FS(–1) 20.00 AHTDKKKK* — — — —
FS(–2) 13.33 AHTKDKKKSETVGQTETRIFISKNKEW*a 15 s0 w0 s0 w0 4.5
Maz C8 Yes Yes Yes 33.3 FS(–1) 20.00 PCTLLAPPSPCWAWTPGGWAAS* 7 s0 w0 s0 w0 9.5
FS(–2) 13.33 FPCTLLAPLPRAGPGLPGGGRPHELLPATSGSR
EPPAGRG*a
17 s0 w0 s0 w0 3.5
Hic1 C10 Yes Yes Yes 31.25 FS(–1) 18.75 DRTFPSPPRIGAI*a 14 s0 w0 s0 w0 5
FS(–2) 12.5 DRTFPSPPELARYNI* 18 s0 w0 s0 w0 4.5
Sdccag1 A11 Yes Yes Yes 25 FS(–1) 25.00 EAPKGKKKSKRTSSCRSRRRTSRCL*a 12 s0 w0 s0 w0 8
FS(–2) 6.25 EAPKGKKKAKEQAAAEAAEEQAAACRCGSQPV
SLCQCQKIL*
16 s0 w0 s0 w0 2.5
Tmem107 G9 Yes Yes Yes 25 FS(–1) 25.00 TQYFGMGGVVENRSQI*a 24 s2 w1 s0 w0 0.5
FS(–2) 6.25 TQYFGMGGWWKIDPKSEGFPHLDLSCTCEIGR KS
HTHPNPPAYKVWRFKCLGWKGL*
21 s0 w0 s1 w2 0.25
Srcin1 C9 Yes Yes Yes 25 FS(–1) 25.00 DEGMWPPPTTS* 6 s0 w0 s0 w0 31
FS(–2) 0.00 VDEGMWPPQQPPEPVPQEGGS* 12 s0 w0 s0 w0 22
Marcks A11 Yes Yes Yes 20 FS(–1) 20.00 SSETPKKKRSAFPSRSPSS*a 12 s0 w0 s0 w0 5.5
FS(–2) 0.00 SSETPKKKEALFLQEVLQAERLLLQEEQEGVGR * 16 s0 w3 s0 w0 0.8
Senp6 A11 Yes Yes Yes 18.75 FS(–1) 18.75 VKCSMKKKIMLSMKMKNQVTENLRARTFVIEP
VRMASGMNASVLYIIQMP*a
27 s10 w12 s0 w2 0.03
































































































































































































































































































































































































































































































































ATadministered mixed together. Separate analysis of CD4 and
CD8 T cell responses demonstrated that Maz (FSP-1) and
Senp6 (FSP-1) elicited CD4 T cell responses, whereas Xirp1
(FSP-1) predominantly induced a CD8 T cell response.
Nacad (FSP-1) induced both CD4 and CD8 T cell responses
(Figure 3C). Characterization of the immunogenic regions of
the FSPs by using shorter peptide fragments from the N-
and C-terminal part of the FSPs demonstrated that the
immunogenic parts of Xirp1 (FSP-1) and Senp6 (FSP-1) are
located at the C-terminus of their FSPs in contrast to Nacad
(FSP-1), the immunogenic region of which resides within
the N-terminus of this FSP. A mixed pattern was observed
for Maz (FSP-1), which is immunogenic as a whole in both
parts of the FSP. Epitope location was correlated with in
silico predictions (Figure 3D). Potential immunogenicity of
wild-type peptide stretches at the N-terminus was excluded
because cross-reactivity with the respective wild-type pro-
tein sequences was observed (Supplementary Figure 2).
Three FSPs—Nacad (FSP-1), Senp6 (FSP-1), and Maz (FSP-
1)—also elicited a humoral immune responses detectable
by peptide enzyme-linked immunosorbent assay
(Supplementary Figure 3).
Early Occurrence of Recurrent Frameshift
Peptide Mutations in VCMsh2 Intestinal Tumors
We evaluated a separate nonoverlapping cohort of 7-
month-old VCMsh2 mice (n ¼ 16 mice, 25 tumors) fed a
regular chow diet to test whether recurrent Maz, Nacad,
Senp6, and Xirp1 FSPs are early mutations that could serve
as candidate vaccine neoantigens. VCMsh2 mice develop
intestinal tumors starting at age 6–9 months.32 When MSI
tumors (n ¼ 16) were tested for FS mutations, moderate
to high frequencies were observed for Nacad (–1) (50%),
Senp6 (–1) (25%), and Maz (–1) (6%). Thus, even tumors
occurring in VCMsh2 mice at young ages have already ac-
quired FSP mutations. These FSP mutations most likely
represent early mutation events. FS mutations in Xirp1
were not detected in MSI tumors of mice at the age of 7
months, but at a high frequency in tumors from older mice
(Table 1).
VCMsh2 Endogenous Adaptive Immunity Against
Recurrent Frameshift Peptide Mutations
To test whether VCMsh2 mice have endogenous adaptive
immunity directed against recurrent FSP neoantigens that
could be boosted by vaccination, we performed splenocyte
IFN-gamma ELISpot for Maz (FSP-1), Nacad (FSP-1), Senp6
(FSP-1), and Xirp1 (FSP-1) in 8- to 15-month-old C57BL/6
and VCMsh2 mice. This showed that, compared to C57BL/6
control or OVA peptide-immunized mice (n ¼ 5 and n ¼ 6,
respectively), VCMsh2 splenocytes pulsed with Maz (FSP-1),
Nacad (FSP-1), Senp6 (FSP-1), and Xirp1 (FSP-1) peptides
in vitro had significantly higher numbers of activated IFN-
gammaþ T cells (Figure 3E). Thus, similar to our previous
findings that LS mutation carriers have endogenous adap-
tive immunity against recurrent FSP neoantigens,23 VCMsh2
mice have endogenous adaptive immunity against recurrent
tumor FSP neoantigens.
Figure 3. FSP immunogenicity. (A) FSP vaccination scheme of C57BL/6 mice. FSP mixes or OVA mix (50 mg each) were
injected subcutaneously biweekly 4 times using CpG ODN 1826 (20 mg) as an adjuvant. The vaccine schedule was chosen to
ensure life-long robust FSP-specific immune responses, including a starting point in early adulthood and booster vaccinations
after the initial priming phase. (B) IFN-gamma (IFN-g) ELISpot analysis. The mean number of spot-forming units (SFUs) for
each mouse is shown for each peptide. OVA mix corresponds to the mixture of the OVA peptide CD4 and CD8 epitope, which
was used as a control in this experimental setup. (C) CD4 and CD8 T cell responses against 4 FSPs. Mean SFU numbers are
presented for each peptide. (D) Epitope mapping of immunogenic peptides. Wild-type peptides (gray), as well as FSPs with
overlapping N/C-terminal sequences (blue boxes, red amino acids), were synthesized and immunogenicity for the regions
where epitopes might be located was determined by IFN-gamma ELISpot. The mean number of SFUs per mouse are shown in
the graph. (E) Endogenous FSP reactivity in Lynch mice. IFN-gamma ELISpot analysis. Each dot represents the number of
SFUs of splenocytes per mouse. VCMsh2 mice were pulsed with a mixture of 4 peptides (FSPs). C57BL/6 (B6) mice pulsed
with either FSPs or OVA peptide served as control. The median, interquartile range/SD, and significance level are indicated.













ATOptimization of Frameshift Peptide–Specific
T Cell Activity With CpG Adjuvant
Several adjuvants recognized for their induction of CD8
T cell responses in mice were tested for compatibility with
the FSP vaccine and for capacity to induce broad T cell re-
sponses across the panel of FSPs, including TLR9 agonists,
STING agonists, and Montanide. Classes of novel adjuvant
compounds have demonstrated the ability to activate type I
IFN from dendritic cells, promote cross-presentation of
soluble antigen to the MHC class I pathway, and have
induced the development of tumor antigen–specific cytolytic
T cells in murine models.39–41 In addition, Montanide is a
water-in-oil emulsion formulation that has a long track re-
cord of being paired with peptide vaccines in preclinical
cancer vaccine investigations, as well as in clinical trials.42,43To assess the FSP-specific T cell induction capability of these
adjuvants, the 4-peptide FSP pool was combined with either
the CpG-C ODN 2395, the CpG-B ODN 1826, the STING
agonist 2030-cGAMP, or formulated with Montanide as an
emulsion. The oil-in-water emulsion AddaVax was combined
with the CpG ODNs and 2030-cGAMP to enhance adjuvant
efficacy.44 We observed robust T cell responses specific to
the panel of FSPs as measured by ELISpot detection of IFN-
gamma spot-forming units to Nacad (FSP-1), Xirp1 (FSP-1),
Maz (FSP-1), and Senp6 (FSP-1) peptides with CpG/Adda-
Vax adjuvant formulations (Supplementary Figure 4).
However, 2030-cGAMP/AddaVax adjuvant yielded substan-
tially lower T cell responses, while the Montanide formu-
lation resulted in negligible spot-forming unit. Further
investigation of the FSP vaccine in mice was conducted with
CpG-B ODN 1826.




ATReduced Tumor Burden and Increased Survival
of Frameshift Peptide Vaccinated VCMsh2 Lynch
Syndrome Mice
Next, we examined whether these 4 immunogenic FSPs
might affect the survival of immunocompetent VCMsh2 mice
that develop small intestinal and colon tumors at the age of
6 months and have a mean life expectancy of about 14
months.32 Six- to 8-week-old VCMsh2 mice were either
vaccinated with 4 FSPs or OVA control and CpG adjuvant
and boosted 3 (Figure 4, Table 2). Tumor burden and
survival analysis of vaccinated (n ¼ 39) and control mice
(n ¼ 36) revealed that recurrent FSP neoantigen vaccination
reduced tumor burden (mean control, 71.84 mg vs vacci-
nated, 47.26 mg, P ¼ .0024, Mann-Whitney) and signifi-
cantly increased survival (control median age, 256 days vs
vaccinated, 327 days, control mean, 263 days vs vaccinated,
351 days; P < .0001, log-rank test).
Further Reduced Tumor Burden and Increased
Survival of Naproxen-Treated and Frameshift
Peptide–Vaccinated VCMsh2 Lynch SyndromMice
FSP vaccination was also tested in combination with ASA
and NAP. VCMsh2 mice were fed a diet including NAP (166
ppm) or ASA (400 ppm), as performed previously.31 As
expected, levels of prostaglandin E2 and other inflammatory
prostaglandins PGD2 and PGF2a were significantly reduced
in intestinal mucosa from these mice (Supplementary
Figure 5). Similar to the previous findings,31 both NAP and
ASA exposure affected intestinal tumor development: NAP
significantly reduced tumor burden and prolonged survival
(P ¼ .0099, Mann-Whitney and P ¼ .0005, log-rank test),
and ASA trended in this direction (P ¼ .23 and P ¼ .081
respectively, Figure 4). FSP vaccination prolonged survival
more effectively compared with ASA (P ¼ .011). The com-
bination of FSP vaccination and NAP significantly prolonged
survival compared to either intervention alone (P ¼ .0016
and P ¼ .0005, log-rank test, respectively) or ASA alone
(P ¼ .0001).
Quantification of Immune Cells in Manifest
Tumors
In total, 22 tumor tissue specimens could be analyzed for
immune cell infiltration (12 from the FSP vaccine group and
10 from the control group). Highest numbers of positively
stained cells were observed for CD4-positive cells. Signifi-
cantly elevated CD4-positive cell counts were recorded in
tumors from the FSP vaccine group compared to tumors
from the control group (P ¼ .048). Similarly, CD8 T cell
counts were significantly higher in the FSP vaccine vs con-
trol group (P ¼ .031). No significant differences were
observed for infiltrating Foxp3-positive or PD-1–positive
cells (Figure 5).
NAP or ASA exposure did not have any significant effects
on immune cell densities. Among tumors from vaccinated
mice, CD8 and CD4 tumor infiltrating lymphocyte counts
tended to be lower in animals exposed to NAP or ASA,
although sample sizes were small.RNA Sequencing Analysis Reveals Increased
Immune Response in the VCMsh2 Intestinal
Tumor Microenvironment
Next, to explore the molecular mechanisms of recurrent
neoantigen vaccination and NSAID, we performed RNA
sequencing using formalin-fixed, paraffin-embedded blocks
from tumor and normal intestinal tissue from VCMsh2
mice. As expected, this revealed substantial numbers of
differentially regulated genes from FSP vaccination, NSAID
cancer prevention, or their combination, in both tumors
and normal intestinal tissue (Supplementary Figures 6 and
7, GSEA accession GSE175744). Only 1 differentially
expressed gene, Ptmap1/Ptma-ps1, was shared among tu-
mors from LS mice that were FSP vaccinated, treated with
NSAIDs, or both (Supplementary Figure 6B). Ptmap1 is a
poorly characterized gene that is ubiquitously expressed,
encodes an open-reading frame with 76% amino acid
identity to Ptma and may be an antagonist of Ptma. Re-
analysis of previously published RNA sequencing
data45,46 showed that PTMA is up-regulated in LS patient
CRCs and premalignant lesions compared to normal mu-
cosa (P ¼ .00015, Wilcoxon 2-tailed) (Supplementary
Figure 6C), suggesting the PTMA/PTMAP1 axis as a po-
tential novel candidate mechanism in LS CRC tumorigen-
esis. There were no significant changes in histologically
normal intestinal mucosa for immune checkpoints PD1/
PDL1, CTLA4, or LAG3 upon FSP vaccination or NSAID
treatment (Supplementary Table 2). In terms of pathway
analysis, as expected, VCMsh2 intestinal tumors compared
to adjacent normal tissue were characterized by up-
regulation of WNT, NOTCH, and MYC signaling, epithelial
to mesenchymal transition, angiogenesis, hypoxia, and
stem cell and proliferation gene pathways, among others
(Supplementary Figure 7). In addition, these tumors had
down-regulation of Th1 IFN-gamma signaling and INF-alfa
signaling, and up-regulation of Th2 CD4þ T cell–mediated
humoral B cell immunity. By comparison, tumors in FSP-
vaccinated mice had notably increased IFN-gamma and
p53 signaling, apoptosis, and reversal of IFN-alfa down-
regulation. Thus, overall in the tumor microenvironment
from FSP vaccinated mice, evidence for a relative up-
regulation of Th1 compared to Th2 signaling pathways
was detected (Supplementary Table 2 and Supplementary
Figure 7). Interestingly, NSAIDs significantly down-
regulated Th2 humoral immune response pathways,
including B cell proliferation, B cell activation, and IgA
production, thereby increasing the relative Th1:Th2 levels
in the tumor microenvironment. In summary, both FSP
vaccination and NSAIDs increased the relative Th1 vs Th2
immune response in the VCMsh2 intestinal tumor micro-
environment, although presumably via different mecha-
nisms, while not significantly impacting immune
checkpoint gene expression levels.Discussion
LS is an important model to study immunopreventive
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FSP vaccine + ASA
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Figure 4. Cancer immunoprevention in Lynch mice. Reduced tumor burden from combination NSAID and recurrent FSP
neoantigen vaccination. (A) Recurrent FSP neoantigen vaccination in combination with NSAID prolongs overall survival of
VCMsh2 mice. Kaplan-Meier survival curves of VCMsh2 mice treated with control (untreated), ASA, NAP, FSP vaccine, FSP
vaccine with ASA, or FSP vaccine with NAP, as described in the Materials and Methods. (B) FSP vaccination and combination
with NSAID treatment decreases tumor burden in VCMsh2 mice. Scatter dot plot representing tumor burden (sum of all in-
testinal tumor weights per mouse [mg]) per mouse in cohorts of control (untreated), treated with ASA, NAP, FSP vaccine, FSP
vaccine plus ASA, or FSP vaccine plus NAP. Both panels present data updated from those originally presented in
Supplementary Figure 3 of Reyes-Uribe et al,30 here including a larger cohort of control and NAP-treated VCMsh2 mice.













ATset of recurrent immunogenic neoantigens. This study pro-
vides the first robust evidence of tumor-preventive potential
for a FSP neoantigen–based vaccine in a LS mouse model.
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Figure 5.Quantitative evaluation of immune cell subtypes. (A) Representative immunohistochemistry stainings. HE, H&E. (B
Quantitative evaluation. Immune cell densities are shown for the antibodies detecting CD4, CD8, Foxp3, and PD-1. Black lines
indicate median values. P values are provided for all comparisons.


















ATimmunogenicity testing; and integrated survival, tumor
burden, and adaptive immune analyses in FSP-vaccinated LS
mice.
As we have shown in a previous clinical phase I/II trial,
FSP neoantigen vaccination is safe, nontoxic, and can elicit
pronounced cellular and humoral immune response in
advanced-stage MSI CRC patients.24 However, data sup-
porting the potential tumor-preventive effect of an FSP-
based vaccine have been lacking. To evaluate FSP-based
vaccination in the preventive setting, we used the VCMsh2
LS mouse model32 and compared survival of vaccinated
mice with controls. We were able to demonstrate enhanced
anti-FSP immunity, reduced tumor burden, and significantly
prolonged survival of VCMsh2 mice receiving the FSP vac-
cine compared to unvaccinated mice.
The VCMsh2 model recapitulates human LS, as these
mice develop MMRD intestinal tumors. These mice have an
intestinal-specific exon 12 deletion of the Msh2 gene by
Villin-Cre and inactivate MMR functions similar to MMRD
found in patients with LS. As an additional advantage, and in
contrast to constitutive MMR-knockout models, the condi-
tional ablation of Msh2 in VCMsh2 mice promotes tumor
development specifically in the intestinal epithelium. This
model also provides benefits in terms of NSAID cancer
prevention studies because dietary ASA can suppress
tumorigenesis in these mice similar to the tumor-protective
effect of long-term ASA observed in humans (CAPP2 trial of
patients with LS28). Despite these similarities, tumor local-
ization appears to be different because VCMsh2 mice usually
develop tumors in the small intestine, whereas colonic tu-
mors predominate in patients with LS. Also, a direct transfer
of human FSPs to the murine model is not feasible due to
genomic differences, in terms of the location of cMNRs in
coding regions and the nucleotide sequence of the respec-
tive genes, and differences in the MHC molecules respon-
sible for antigen presentation. Therefore, we established a
comprehensive database of murine cMNRs, providing a
unique source of murine candidate genes and derived FSPs.
Using this genome-wide computational approach, we
were able to select 4 candidate FSPs, which are shared by
different murine MSI intestinal tumors, and validated their
immunogenicity in vivo. The 4 FSPs Nacad (FSP-1), Maz
(FSP-1), Senp6 (FSP-1), and Xirp1 (FSP-1) generated
cellular and humoral immune responses in naïve mice.
ELISpot analyses showed CD8 T cell–specific response for
Xirp1 (FSP-1), a mixed CD4/CD8 T cell response for Nacad
(FSP-1), and a CD4 T cell–specific response for Maz1 (FSP-
1) and Senp6 (FSP-1), partially overlapping with in silico
prediction of MHC binding motifs. Three of these 4 FSPs also
elicited humoral immune responses, which were only ab-
sent for Xirp1 (FSP-1), consistent with the observed re-
striction of cellular immune responses to CD8, but not CD4
T cells, which play a major role in mediation of humoral
immune responses. When analyzing immune cell infiltration
of tumors in VCMsh2 mice receiving the FSP vaccine, we
observed a significantly elevated density of CD4-positive
and CD8-positive T cells in tumors compared to non-
vaccinated control mice; densities for CD4-positive T cells
were generally higher than the density of CD8-positive Tcells. These findings are consistent with a predominance of
CD4 responses triggered by FSP vaccination, as observed in
human patients with MSI CRC who were vaccinated with a
trivalent FSP vaccine.24 Previously, CD4-positive T cell re-
sponses were shown to be predominant and associated with
clinical response in “personalized” melanoma and glioblas-
toma patient neoantigen and tumor-associated antigen
vaccine trials.47–49 Thus, our findings support important
roles for CD4-positive (in addition to CD8-positive) T cells in
durable clinical responses to tumor vaccines.
The fact that cMNR mutations affecting the genes Nacad,
Maz, Senp6, and Xirp1 were found to be recurrent across
tumors may suggest a functional role of these mutations as
drivers of tumor development. Although some evidence of
involvement in tumor development exists for the genes Maz
and Senp6,50–53 very limited functional data are available for
Nacad and Xirp1. Thus, further studies are required to
elucidate a potential functional contribution of these mu-
tations to MSI tumor progression.
Although, as outlined above, the precise amino acid
sequence differs between murine and human FSP neo-
antigens, the observed immunopreventive effects support
the hypothesis that vaccination with shared FSP neo-
antigens may be a powerful approach for cancer prevention
in LS. In particular, it is notable that vaccination with only a
limited number of FSPs combined with relatively low dose
of NAP significantly delayed tumor formation and prolonged
overall survival in LS mice, providing a rational approach for
combination cancer- and immuno-prevention.
Our study addresses, for the first time to our knowledge,
the important question of whether FSP vaccination and
NSAIDs are synergistic or antagonistic in LS cancer pre-
vention. The increased survival and reduced tumor burden
of mice receiving both FSP vaccination and NSAID treatment
is consistent with a role for combined chemo- and immu-
noprevention to reduce tumor burden in a practical manner.
Our observations suggest that the combination of FSP
vaccination and NSAID treatment is beneficial, possibly by
partially complementary mechanisms, which need to be
elucidated in future studies.
By analyzing transcriptomic pathways altered by FSP
vaccination and NSAIDs, we identified a differentially
expressed gene, Ptmap1, that was differentially regulated in
tumors from LS mice that were FSP vaccinated, treated with
NSAIDs, and then further up-regulated by combined treat-
ment. PTMA is a nuclear oncoprotein transcription factor
that is up-regulated in solid tumors, including CRC, and is
functionally associated with CRC poor prognosis.54 PTMAP1
overall remains poorly characterized. Because PTMAP1 is
highly homologous to PTMA at the protein level, it may
antagonize PTMA oncogenic transcriptional program func-
tions. However, these findings are exploratory and further
studies are needed to assess the mechanistic role of the
PTMA/PTMAP1 axis in LS CRC tumorigenesis.
In terms of transcriptomic pathways, both FSP vaccina-
tion and NSAIDs increased the relative Th1 vs Th2 T cell
immune response in the VCMsh2 intestinal tumor microen-
vironment, while not significantly impacting critical immune
checkpoint gene expression levels, which for PD-1 was




ATconfirmed by quantitative immunohistochemistry
(Figure 5). Thus, elevated Th1 T cell activation in the tumor
microenvironment is the most likely immune surveillance
mechanism to account for the observed reduced tumor
burden in FSP-vaccinated, NSAID-treated, and combination-
treated mice.
This study has several limitations. Our study was con-
ducted in mice that have defined MHC molecules, whereas
LS patients have much broader HLA (class I and class II
MHC) diversity. It remains to be demonstrated whether a
broader spectrum of shared FSPs in combination with other
cancer prevention approaches might represent an even
more effective strategy to prevent LS tumors in patients
with greater HLA diversity. Although CpG1826 showed best
results among the 4 adjuvants screened in LS mice, it is
unclear whether alternative adjuvants might be more
effective for FSP vaccination in human LS patients. In the
same context, the most effective boosting regimen is still
unknown. Additional preclinical studies addressing these
questions will be required before large-scale LS immuno-
prevention trials are carried out.
In summary, our results strongly support the concept of
FSP neoantigen vaccination as a promising strategy for
immunoprevention of intestinal MMRD tumors, particularly
in the setting of LS. We provided the first evidence that
vaccination with a small number of shared FSP neoantigens
alone effectively delays formation of naturally occurring
tumors and prolonged survival in an LS mouse model.
Furthermore, as NSAID use is the current choice of care for
patients with LS, we showed that this benefit can be
enhanced significantly in a cooperative manner by
combining FSP vaccination with NSAID treatment. Clinical
translation of this concept of neoantigen-based tumor pre-
vention is encouraging, and our studies support further
preclinical and clinical studies to translate this benefit for LS
immunoprevention.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://doi.org/10.1053/
j.gastro.2021.06.073.References
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DNA/RNA isolation of VCMsh2 mouse tumors
from formalin-fixed, paraffin-embedded tissues. For
determination of cMNR mutation frequency, formalin-fixed
paraffin-embedded (FFPE) tissue blocks were generated
from VCMsh2 mice after they had developed intestinal tu-
mors at the age of 7–15 months (n ¼ 25). Each tissue
section contained normal mucosa and tumor tissue. To
ensure enrichment of tumor cells (>80%), tissue sections
were microdissected. Sufficient amounts of DNA and RNA
were obtained by pooling microdissected tissues from
several consecutive sections. DNA and RNA from matched
normal/tumor tissues were isolated using the QIAmpDNA
FFPE Tissue and the RNeasy Mini Kits (Qiagen).
Coding mononucleotide repeat mutation ana-
lysis. Oligonucleotide primers for the amplification of
cMNR sequences were designed using the search tool
Primer 3 (http://www.broadinstitute.org, http://bioinfo.ut.
ee/primer3/). Other considerations for primer design
included considering the requirement for small amplicon
size (100–140 bp) required for robust amplification from
genomic DNA of murine FFPE tissues. One primer of each
primer set carried a fluorescent (fluorescein isothiocyanate)
label at the 50-end. FS mutations were identified by poly-
merase chain reaction–based DNA fragment length analysis.
Instability was scored qualitatively, if novel peaks were
obtained in the tumor compared to normal tissue, or
quantitatively by processing extracted peak height profiles
by a custom R algorithm.
Preparation of peptides with CpG adjuvant for
vaccination of C57Bl/6 mice. For preparation of the
vaccine formulations, lyophilized peptides (OVA or equi-
molar concentrations of Senp6, Xirp1, Maz, and Nacad)
were resuspended in 20% dimethyl sulfoxide containing
distilled phosphate-buffered saline to achieve a final con-
centration of 5 mg/mL and stored at –80C. Lyophilized
OVA peptide was resuspended in sterile water to achieve a
final concentration of 4 mg/mL each. Then, 5 mL of OVA
257–264 (4 mg/mL) was mixed with 5 mL of OVA 323–339
to achieve a final concentration of 2 mg/mL each and stored
at –80C. The lyophilized adjuvant (CpG ODN 1826) was
resuspended in sterile water to achieve a final concentra-
tion of 2 mg/mL and stored at –80C.
Adjuvant optimization in wild-type C57BL/6
mice. FSPs (OVA or Senp6 [FSP-1], Xirp1 [FSP-1], Maz
[FSP-1], and Nacad [FSP-1]) were synthesized at Pierce
(Thermo Fisher), received with certificates of analysis, and
stored lyophilized at –80C; or by GenScript at 90% purity
and solubilized as a pool at 5 mg/mL each peptide in
dimethyl sulfoxide. CpG-B ODN 1826, CpG-C ODN 2395,
2030-cGAMP, and AddaVax were all purchased from Inviv-
oGen. CpG ODNs and 2030-cGAMP were first mixed with
AddaVax and then combined with FSPs to prepare vaccines
in which 100-mL dose volume per mouse contained 50 mg
each of 4 FSPs, 50% v/v AddaVax, and either 20 mg 1826,
20 mg 2395, or 15 mg 2030-cGAMP. FSPs were also
solubilized in 1 phosphate-buffered saline and combined
with Montanide ISA-720 (Seppic) in a 30:70 v/v ratio. Sy-
ringes (3 cc) were separately loaded with the aqueous
peptide phase or with Montanide and then connected with
an I-connector. Emulsion was generated by cycling total
volume of both phases back and forth between the 2 sy-
ringes 20 times, 8 seconds per cycle, and then 60 times, 2
seconds per cycle, until the emulsion adopted a creamy
viscous appearance. After briefly mixing by vortex, vaccines
were administered to mice. Ten-week-old female C57BL/6
mice (Charles River) were randomized into groups of 8
animals and immunized on study days 0, 14, and 28 (2-
week intervals). Mice were injected subcutaneously in
alternate flanks with 100-mL dose volumes. Spleens were
harvested on day 42 and the obtained cell suspensions were
analyzed by IFN-gamma ELISpot, as described in
Supplementary Methods.
Interferon-gamma enzyme-linked immunosor-
bent spot assay. Spleens were harvested and dissociated
using the GentleMACS Dissociator (Miltenyi). Cell suspen-
sions were subsequently washed with Hank’s balanced salt
solution (Gibco) þ 5% fetal bovine serum (Gibco), lysed to
remove red blood cells with ACK Lysing Buffer (Thermo-
Fisher), and filtered through 70-mm strainers (BD Bio-
sciences). Cells were counted with the Vi-Cell analyzer
(Beckman Coulter) and resuspended in RPMI-1640
(Thermo-Fisher) þ 10% fetal bovine serum and resus-
pended in culture medium (RPMI-1640 þ 10% fetal bovine
serum ) at 5e6/mL. The R&D Systems mouse IFN-gamma
ELISpot assay was performed according to the manufac-
turer’s specifications. After blocking plates with culture
media, stimulants were added to plates, including 5 mg/mL
individual FSP peptides (synthesized by GenScript) and
OVA SIINFEKL peptide (InvivoGen). Lastly, 2.5e5 spleno-
cytes were added per well in triplicate in a volume of 50 mL
and plates were incubated in a 37C, 5% CO2 incubator for
42–48 hours. ELISpot plates were then developed according
to the manufacturer’s protocol. Plates were washed with the
BioTek EL405 plate washer. After a developing step, plates
were air-dried for 24 hours and then imaged and spots
counted on an ImmunoSpot Analyzer (C.T.L.) using Immu-
noCapture software.
Enzyme-linked immunosorbent assay of frame-
shift peptide humoral immunogenicity. After sacri-
ficing, whole blood was collected from mice via cardiac
puncture and centrifuged to obtain serum for enzyme-
linked immunosorbent assay (ELISA) analysis. Ninety-
six-well ELISA plates were coated with the peptide of
interest, and serially diluted mouse sera were added into
the wells in quadruplicates. The optical density of the
ELISA reaction was measured at 405 nm in an ELISA
reader with a reference wavelength of 620 nm. Reactions
significantly above background after subtraction of twice
the SE of the peptide only background and no-peptide
antigen only control values were regarded as positive.
Titration was performed to quantify the amounts of
neoantigen-specific IgG antibodies in mouse sera for all 4
peptides.
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Murine intestinal tumor analysis. For intestinal tu-
mor analysis, a general survey was performed of mice for
gross pathology of any abdominal or thoracic cavity organ.
Euthanized mice were dissected and small intestines and
colons were washed in ice-cold distilled phosphate-buffered
saline. Normal intestinal tissue and adenomas were
dissected. Lesions were then counted, dissected out,
weighed, and either flash frozen in Optimal Cutting Tem-
perature medium for RNA or embedded in paraffin for H&E
for further histologic analysis by a pathologist. All tumors
were confirmed by histopathological evaluation. For each
mouse, tumor multiplicity, weight, and tumor burden (sum
of tumor weights per mouse) data were included in the
analysis. For all mice, age at the time of euthanasia was
recorded for survival analysis. Mice that died or were
euthanized due to unrelated causes (eg, dermatitis) were
excluded from survival analysis. DNA/RNA isolation was
carried out using QiaAmp DNA and RNeasy RNA Isolation
kit, respectively, in preparation for follow-up studies in the
future.
Immunohistochemistry staining. For quantification
of tumor infiltrating lymphocyte densities, tissue sections
were deparaffinized and rehydrated by submerging for 5
minutes in 3 different 100% xylene baths, two 100%
ethanol baths, one 96% ethanol bath, and one 70% ethanol
bath, and 1 deionized water bath. Antigen retrieval was
carried out by microwaving the slides 3 times for 10 mi-
nutes at 560 watts, either in a 10 mM citric acid mono-
hydrate solution at pH 6.0 (for CD3) or in a Tris-EDTA
solution at pH 8.5 (for CD4, CD8, Foxp3, and PD-1).
Endogenous peroxidase was quenched by treating the
slides with 0.6% hydrogen peroxide in methanol for 20
minutes. After blocking the nonspecific binding with 10%
horse serum for 30 minutes, the slides were incubated
overnight at 4C with the primary antibody (for CD3: clone
SP7 abcam ab16669; for CD4: clone 4SM95 ThermoFisher
Scientific #14-9766-82; for CD8: clone 4SM15 Thermo-
Fisher Scientific #14-0808-82; for Foxp3: clone FJK-16s
ThermoFisher Scientific #14-5773-82; for PD-1: clone
EPR20665 abcam ab214421). The sections were incubated
with the biotinylated secondary antibody (for CD3 and PD-
1: Vector Laboratories BA-1100; for CD4, CD8, and Foxp3:
Vector Laboratories BA-9401) for 30 minutes at room
temperature. The Vectastain Elite ABC kit (Vector Labora-
tories) was used for the avidin-biotin complex formation.
Slides were incubated with the avidin-biotin complex for 30
minutes at room temperature. The 3,30-diaminobenzidine
tetra hydrochloride chromogen (DAKO) reaction was
allowed to develop for 5 seconds up to 15 minutes under
visual microscopy control, depending on the antibody used.
Hematoxylin was used to counterstain the sections, and the
slides were covered with a cover glass-mounted with
AquaTex.
RNA sequencing analysis. Total RNA for library
preparation and sequencing analysis was purified from
microdissected VcMsh2 FFPE tumor and normal intestinal
tissue using the FFPE RNA Isolation Kit (Qiagen) that
included a genomic DNA elimination step. Coding RNA
transcripts were enriched using mouse exome panel hy-
bridization (Twist Biosciences). Size, concentration, and
integrity was verified using Agilent 2100 Bioanalyzer (Agi-
lent Technologies). Libraries were generated using Illumi-
na’s TruSeq RNA sample Prep Kit v3, following
manufacturer’s protocol. Sequencing of 8–10 pM of each
library was done on the NovaSeq sequencer as 75-bp
paired-end read runs.
Quality control of raw sequencing reads was performed
with fastqc.1 Spliced alignment of the reads to the refer-
ence genome was accomplished with STAR,2 followed by a
second round of quality control using RSeQC.3 Mouse
genome build Mm.10 and the corresponding GENCODE
annotation, version 25, were used as reference. Mapped
reads were quantified at the gene level as a raw count
matrix using featureCounts from Subread4 using fracO-
verlap 1 (only entire reads overlapping to annotation
feature are counted). Raw feature counts were normalized
and differential expression analysis carried out using
DESeq2,5 excluding genes mapping to mitochondria. Dif-
ferential expression rank order was used for subsequent
gene set enrichment analysis, performed using the clus-
terProfiler package in R. Gene sets queried included the
Hallmark, Canonical Pathways, and GO Biological Processes
Ontology collections available through the Molecular Sig-
natures Database.6
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Supplementary Figure 1.Mutation frequency of coding microsatellites derived from mouse genome analysis.
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Supplementary Figure 2. Cross-reactivity with wild-type peptides. IFN-gamma (IFN-g) ELISpot was carried out with the wild-
type peptide and the corresponding FSP of interest using splenocytes from immunized mice. The mean number of cells that
are secreting IFN-g per 1.5  106 cells per mouse is shown on the y-axis and the FSPs and wild-type peptides are indicated on
the x-axis.
Supplementary Figure 3. Humoral immune responses. Serum (50 mL) from vaccinated mice was analyzed by peptide-specific
(FSPs and wild-type peptides) total IgG ELISA. Optical density (OD) was measured at 405 nm in an ELISA reader with a
reference wavelength of 620 nm. The mean OD value is shown for each mouse.























































































































































Supplementary Figure 4. Adjuvant promotion of FSP-specific T cell responses. Mice were immunized subcutaneously in
inguinal area with 200 mg FSP peptide pool alone or adjuvanted with 20 mg CpG-2395 þ 50% v/v AddaVax, 20 mg CpG-1826þ
50% v/v AddaVax, 15 mg 2’3’-cGAMP þ 50% v/v AddaVax, or 70% v/v Montanide on days 0, 14, and 28. Spleens were
harvested on day 42 and splenocytes restimulated in vitro with individual FSP peptides or OVA peptide as a negative control
for 48 hours and spot-forming units (SFUs)/1e6 cells analyzed via ELISpot. Data are reported as geometric means þ 95%
confidence intervals. Statistical comparisons are between unstimulated cells and all other groups and were generated using 1-
way analysis of variance nonparametric analysis with the Kruskal-Wallis multiple comparisons test. *P < .05; **P < .01; ***P <
.001; ****P < .0001.
Supplementary Figure 5. Prostaglandin expression. Relative
abundance of inflammatory prostaglandins in intestinal
mucosae of mice vaccinated with FSP alone (black bar) or in
combination with ASA (light gray bar) or NAP (dark gray bar).
SD and significance levels are indicated (****P < .00001). ns,
not significant.
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Supplementary Figure 6. Transcriptional profiling of tumors (T) and normal intestinal tissue (N) derived from untreated VcMsh2
mice on Western diet (R), treated with NAP or ASA (NSAID; N), treated with FSP vaccine (RV), or combination NSAID and FSP
vaccine (NV). (A) Heatmap representing all identified differentially expressed genes (false discovery rate [FDR]–adjusted P value
< .05) between treatment groups and untreated mice in normal tissue (left) and tumor tissue (right). (B) Volcano plots depicting
differential expression patterns identified in treated mice relative to untreated mice in tumor tissue (top) and normal tissue
(bottom). Genes with significantly changing expression (FDR-adjusted P value < .05) with treatment are shown in color as
labeled in (A). (C) RNA transcript levels for PTMA in human LS patient normal colorectal mucosa and colorectal adenomas/
adenocarcinomas, measured in re-analysis of RNA sequencing data published in Chang et al7 and Bommi et al.8
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Supplementary Figure 7.Gene set enrichment analysis (GSEA) enrichment plots and scores. (A) Selected GSEA enriched
pathways comparing control mouse intestinal tumors and normal tissue (R.T vs. R.N). (B) Selected GSEA enriched pathways
comparing NSAID-treated mouse intestinal tumors and normal tissue (N.T vs. N.N). (C) Selected GSEA enriched pathways
comparing FSP vaccinated mouse intestinal tumors and normal tissue (RV.T vs RV.N).
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Supplementary Figure 7. Continued
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Supplementary Figure 7. Continued
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Supplementary Table 1.List of cMNR Primers
Gene Primer (50 > 30) Antisense; Sense
Adamtsl1_A1 CTG GAT GTC CTC CTC CAC AC
Adamtsl1_S1 CTG ATG ACG CCC CTT GCT TC
Armcx5_A1 CCA GTT CCC ATC TGG AGG TA
Armcx5_S1 TGA ACC CCC AGA TAC ATT CG
Bcas3_A1 ACG CAG GCT TTG TTA CTG TT
Bcas3_S1 TCC GTG TAC TTC TGG AGC AT
C79407A ATA CGT GAT GCT GGC CTT TT
C79407S AAG ACC AGA CAG GAA ACA GCA
Ccdc112_A1 GCA CAC TGA CAC GCA CAA T
Ccdc112_S1 CGG GAA GAA CTC TGG ATG AA
Cd300c_A1 CTG AGG CAC TGG TCT TGA CA
Cd300c_S1 ACT GTG GGG GAG TCA CTC AG
Chd2_A1 ATG CAG GGA CGG TAA AGA CA
Chd2_S1 CAA GAT CTC TGG GGT TCA GG
Chrnb2_A1 TGC CAG TTC CCA CAT AGG AT
Chrnb2_S1 TGC TGC CAG ACA ATC ACA TT
Cyp4a30b_A1 CCC TGA GCG GTT AAA CTG AG
Cyp4a30b_S1 CAT CAA GTC CCT CCA GCA GT
Eml2_A1 GTC GTA GAG GCC GCA GAA
Eml2_S1 GAA CGA AGG GCG TTG CTA T
Esp31_A1 CAC TGG GTC CAT TAC TTG GAG
Esp31_S1 TCC TGA GAT GTC ATT CAA CCT C
Fam60a_A1 TCC TAA ATT GGG GAT GGT GA
Fam60a_S1 TGC TGC TTG TGA AAA GAT GG
Fam71a_A1 GCT TTT GAC GCT GAC CTT GT
Fam71a_S1 AGT ACC TAT GCC ATC CCA GC
Grb14_A GGC TGA GGC TTG CTT TAC TC
Grb14_S GCA TTT GCA GCT TTT CAG TG
Grk4_A1 CAT GGC TTC ACC TTT CCT CT
Grk4_S1 AAA CTA GGT TTG TGC CTG TCA AG
Il1f9_A1 AGC CAT ACC TGA GAT GTG TGT
Il1f9_S1 GGC ACC AGA ACA AGA TCA CG
Kcnma1_A TGC TTA CCT CAT CAG CTT CG
Kcnma1_S CAC AAG CTG CCT GTA TTT GC
m5730596B20Rik_A1 TCA ATG AGG AGA ATG TGC AGA C
m5730596B20Rik_S1 CAG GTT GGA CTC ACT GGG TC
mA230052G05Rik_A1 GTC TCA GAC CGT GGC AGA AG
mA230052G05Rik_S1 GCT CTG TCC TGC TTT GTC CT
Maz_A1 CAA AGA AGC GGG ACT GGA G
Supplementary Table 1.Continued
Gene Primer (50 > 30) Antisense; Sense
Maz_S1 GTT CCC CGT GTT CCC TTG
mB2m_A1 TCCTTGCTGAAGGACATATCTGA
mB2m_S1 GAGAATGGGAAGCCGAACAT
mBud13_A1 CTT GGT CTG TTC CGT GGT G
mBud13_S1 CAC AGG AGA TTT CAT AGA CGC TT
mCdkl3_A1 AGG AAG GAA TTG TCA AGC TTG T
mCdkl3_S1 GGC GAT TGT GAG GGG AAG AA
mDclre1c_A1 CAC CTG CCT TGC CTC TAC C
mDclre1c_S1 CAT TCA CAT GCG CAC ACA CA
mDdhd2_A1 TCT AAA TCT TCG CCT TAC CTT TGG
mDdhd2_S1 GGA TAC GTA CAT GCT TGC AGT
mDefb34_A1 TCT CCC ATT AAT CCT GCT GCA
mDefb34_S1 AGC CAC ATG TGA AGC AGA GT
mElavI3_A1 GTC AGT GGC TCC ATT TGT CC
mElavI3_S1 CGG GTA CGA CCT GTT TTC TC
mGlis2_A1 GGT GAG AGG CAC TTG TCC TT
mGlis2_S1 TTC CAG CCA CTT CGC TAT TT
mGlrx2_A1 TGG CGA CTA TCC ACA TCA TTC A
mGlrx2_S1 GGA CAC TCA CAG GCT TCA CA
mHic1_A1 AGA TAT CGG ACC TGG GAG TCC
mHic1_S1 TCC CTG GCT TAA GAG TTC CTC
mLrp5_A1 GGG AAG AGG TGG CAG TAA CTC
mLrp5_S1 CCT GGA CTT GAA TTC GGA CT
mMarcks_A1 GGT CGC TCC CTC TGC TTC AG
mMarcks_S1 GTC CGC CTC CTC CAC GTC
Mndal_A1 CCT GAT CCT GGG TGA GCT TA
Mndal_S1 TCA GGG TTC AAT TTC CAA CAC A
mRif1_A1 ACA TAC TTT GGC CGA CAG TTT C
mRif1_S1 GGC ATG GAA AGA AAA TCA AGT GG
mSlc35f5_A1 CCC CAC ACA GCA CAC ACA T
mSlc35f5_S1 AGA CTG TAG GGA AAT TGA CTG C
mSmap1_A1 GGC TTT TCT GGC TCC TTT TCT C
mSmap1_S1 AGT CTG TTC TGT TGG ACA TGT GA
mSpice1_A1 TGT GGG CAG AGA GAG CAA AC
mSpice1_S1 TCT GAG TCT CTA GTG GGC TCA
mSrcin1_A1 AAA ATC CAA GCC TTT GCT GA
mSrcin1_S1 CTG CTC CTC ACT CTC CCA AC
mTmem107_A1 TCT AGG TGG GGG AAA CCT TC
mTmem107_S1 GAG CGA TGG GAA TGT ACC AC
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Supplementary Table 1.Continued
Gene Primer (50 > 30) Antisense; Sense
mXirp1_A1 GCC AAC TCG CTC ATA GGG TA
mXirp1_S1 CCA CCA ACA AGA GCA ACA GA
Nacad_A1 CTG TCC CTC TGT CCG TCA AT
Nacad_S1 ACG CTC ACT CGG CTT GAT AG
Phactr4_A CCA GGG CTT TGC TCA AAC TA
Phactr4_S ATC TTC AAG CCG TGG AAA TG
Ptpn21_A CGC TCT GGT GGA CAC TTC TT
Ptpn21_S TTT GAA AGG TGT CTG GGT ACG
Rfc3_A AGG AGC AGT TTA CCT GGG ATT
Rfc3_S TTG GCA GTA GTG ATT TGG TGA
Rgs12_A1 GGC AGA GCA GGT TTA AGG ACT
Rgs12_S1 CCG CCT TTC AAA GAG AGA AG
RIKC030005K15_A1 AGC TTA GGG AGG AAG GCT GT
RIKC030005K15_S1 GAG ACA GTG TTT CAA AAA TCT CCA
Sdccag1_A CTG ACA GGC TGA GAT CCA CA
Sdccag1_S GCC AGC ATT GAG AAC AGT GA
Senp6_A CAA ATG TCC TGG CAC GTA GA
Senp6_S GTG AGC CTT GTT ACC GGA GA
Smarcc2_A1 TCC CTT CAA AGG AAC CAG AA
Smarcc2_S1 CAG CCA CAA CAA GCT GGA G
Tgfb1i1_A1 GCC GTG ACC ATG TAT GGA A
Tgfb1i1_S1 ACA GAG CCA CAA AGC TGG AT
Wfdc8_A1 GTG TTA GCG GTG CTG AGG A
Wfdc8_S1 TCT CGC CTC ACA GAC AAC TG
Zfand4_A1 GTG GGT GGG TAG GGA ATT G
Zfand4_S1 CCT AAA GTG CCA GAG GGA TG
Zfp457_A1 TGG GTA TGG GGG ACT TTT G
Zfp457_S1 TGT GGC AAG GAC TTC CAT TA
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